Lund, Sweden - 11 September 2026 - Camurus today announced that the Nomination Committee for the Annual General Meeting (AGM) 2027 consists of the following persons, who together represent about 38 percent of the total number of shares and votes in Camurus based on the last known shareholder information:
The Nomination Committee's proposals will be presented in the Notice to the AGM 2027 and on Camurus' website, www.camurus.com.
Shareholders who wish to submit proposals to the Nomination Committee are welcome to contact the Nomination Committee at the company's address, Rydbergs torg 4, SE-224 84, Lund, Sweden. Proposals shall be submitted in due time before the AGM, but not later than 11 February 2027, to ensure that the proposals can be adequately considered by the Nomination Committee.
The AGM 2027 in Camurus will be held at 5:00 pm CEST on 13 May 2027 in Lund. Shareholders who want to have a matter addressed at the AGM 2027 must submit such a proposal to the same address as above (subject "Annual General Meeting 2027") by 25 March 2027 at the latest.
About Camurus
Camurus is an international, science-led biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for improving the lives of patients with severe and chronic diseases. New drug products with best-in-class potential are conceived based on the company's proprietary FluidCrystal® technology and its extensive R&D expertise. The R&D pipeline includes products for the treatment of dependence, pain, cancer, and endocrine diseases. Camurus has operations across Europe, the US, and Australia, with headquarters in Lund, Sweden. The company's shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com and LinkedIn.
For more information
Per Olof Wallström, Chairman of the Board
Tel. +46 709 42 95 20
p.o.wallstrom@telia.com
The information was submitted for publication at 07:00 am CET on 11 September 2026.